%0 Journal Article %A Adrian I. Campos %A Aoibhe Mulcahy %A Jackson G. Thorp %A Naomi R. Wray %A Enda M. Byrne %A Penelope A. Lind %A Sarah E. Medland %A Nicholas G. Martin %A Ian B. Hickie %A Miguel E. RenterĂ­a %T Understanding genetic risk factors for common side effects of antidepressant medications %D 2021 %R 10.1101/2021.07.12.21260397 %J medRxiv %P 2021.07.12.21260397 %X Major depression is one of the most disabling health conditions internationally. In recent years, new generation antidepressant medicines have become very widely prescribed. While these medicines are efficacious, side effects are common and frequently result in discontinuation of treatment. Compared with specific pharmacological properties of the different medications, the relevance of individual vulnerability is understudied. We used data from the Australian Genetics of Depression Study to gain insights into the aetiology and genetic risk factors to antidepressant side effects. As expected, the most commonly reported longer-term side effects were reduced sexual function and weight gain. Importantly, participants reporting a specific side effect for one antidepressant were more likely to report the same side effect for other antidepressants, suggesting the presence of shared individual or pharmacological factors. Depression Polygenic Risk Scores (PRS) were associated with side effects that overlapped with depressive symptoms, including suicidality and anxiety. Body Mass Index PRS were strongly associated with weight gain from all medications. PRS for headaches were associated with headaches from sertraline. Insomnia PRS showed some evidence of predicting insomnia from amitriptyline and escitalopram. Our results suggest a set of common factors underlying the risk for antidepressant side effects. These factors seem to be, at least in part, explained by genetic liability related to depression severity and the nature of the side effect. Future studies on the genetic aetiology of side effects will enable insights into their underlying mechanisms and the possibility of risk stratification and prophylaxis strategies.Competing Interest StatementIBH has been commissioner of Australia National Mental Health Commission, Co-director of Health & Policy at the Brain & Mind Centre, University of Sydney. Led community-based and pharmaceutical industry-supported projects (Wyeth, Eli Lilly, Servier, Pfizer, AstraZeneca) focused on the identification and better management of anxiety and depression. Member of the Medical Advisory Panel for Medibank Private until October 2017. A board member of Psychosis Australia Trust. A member of the Veterans Mental Health Clinical Reference Group. Chief Scientific Advisor to and an equity shareholder in Innowell. AIC, AM, NGM, JGT, PAL, SEM, PL, JGT, NRW, EMB and MER have nothing to disclose.Funding StatementData collection for AGDS was possible thanks to funding from the Australian National Health & Medical Research Council (NHMRC) to NGM, NRW, SEM, IHB, EMB, PAL (GNT1086683) and Medical Research Future Fund (APP1200644). MER thanks the support of NHMRC and the Australian Research Council (ARC) through an NHMRC-ARC Dementia Research Development Fellowship (GNT1102821). SEM is supported in part by NHMRC investigator grant APP1172917.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The QIMR Berghofer Medical Research Institute Human Research Ethics Committee approved all questionnaires and research procedures (project 2118).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data on prevalence and effects described in this manuscript is available in the supplementary data. GWAS summary statistics used in this study are publicly available and have been disclosed but are also available upon request. Code related to this study data analysis is available upon request from the authors. Access to the AGDS data is restricted due to the ethical guidelines governing the study. %U https://www.medrxiv.org/content/medrxiv/early/2021/07/16/2021.07.12.21260397.full.pdf